Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R)(brand name in China: "DAYVIGO(R) generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in China […]